622 related articles for article (PubMed ID: 1673721)
1. Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis.
Singh G; Fries JF; Williams CA; Zatarain E; Spitz P; Bloch DA
J Rheumatol; 1991 Feb; 18(2):188-94. PubMed ID: 1673721
[TBL] [Abstract][Full Text] [Related]
2. [Retrospective study of adverse events in patients with rheumatoid arthritis treated with second-line drugs].
Jiang L; Zhao N; Ni L
Zhonghua Liu Xing Bing Xue Za Zhi; 2002 Jun; 23(3):213-7. PubMed ID: 12411093
[TBL] [Abstract][Full Text] [Related]
3. Longterm combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy.
Rau R; Schleusser B; Herborn G; Karger T
J Rheumatol; 1998 Aug; 25(8):1485-92. PubMed ID: 9712088
[TBL] [Abstract][Full Text] [Related]
4. Rheumatoid arthritis: a pharmacologic overview.
Pinals RS
Am Fam Physician; 1988 Mar; 37(3):145-52. PubMed ID: 2894754
[TBL] [Abstract][Full Text] [Related]
5. Disease modifying antirheumatic drugs in early rheumatoid arthritis: a longterm observational study.
Papadopoulos NG; Alamanos Y; Papadopoulos IA; Tsifetaki N; Voulgari PV; Drosos AA
J Rheumatol; 2002 Feb; 29(2):261-6. PubMed ID: 11838843
[TBL] [Abstract][Full Text] [Related]
6. Variability in individual responses of 532 patients with rheumatoid arthritis to first-line and second-line drugs.
Pincus T; Callahan LF
Agents Actions Suppl; 1993; 44():67-75. PubMed ID: 8103964
[TBL] [Abstract][Full Text] [Related]
7. Drugs for rheumatoid arthritis.
Med Lett Drugs Ther; 1989 Jun; 31(795):61-4. PubMed ID: 2567489
[No Abstract] [Full Text] [Related]
8. Adverse events with disease modifying antirheumatic drugs (DMARD): a cohort study of leflunomide compared with other DMARD.
Cannon GW; Holden WL; Juhaeri J; Dai W; Scarazzini L; Stang P
J Rheumatol; 2004 Oct; 31(10):1906-11. PubMed ID: 15468352
[TBL] [Abstract][Full Text] [Related]
9. Methotrexate, hydroxychloroquine, and intramuscular gold in rheumatoid arthritis: relative area under the curve effectiveness and sequence effects.
Hurst S; Kallan MJ; Wolfe FJ; Fries JF; Albert DA
J Rheumatol; 2002 Aug; 29(8):1639-45. PubMed ID: 12180722
[TBL] [Abstract][Full Text] [Related]
10. Disappointing longterm results with disease modifying antirheumatic drugs. A practice based study.
Galindo-Rodriguez G; Aviña-Zubieta JA; Russell AS; Suarez-Almazor ME
J Rheumatol; 1999 Nov; 26(11):2337-43. PubMed ID: 10555887
[TBL] [Abstract][Full Text] [Related]
11. Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritis.
Schiff MH; Whelton A
Semin Arthritis Rheum; 2000 Dec; 30(3):196-208. PubMed ID: 11124283
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study.
Aletaha D; Smolen JS
J Rheumatol; 2002 Aug; 29(8):1631-8. PubMed ID: 12180721
[TBL] [Abstract][Full Text] [Related]
13. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use.
Proudman SM; Keen HI; Stamp LK; Lee AT; Goldblatt F; Ayres OC; Rischmueller M; James MJ; Hill CL; Caughey GE; Cleland LG
Semin Arthritis Rheum; 2007 Oct; 37(2):99-111. PubMed ID: 17391739
[TBL] [Abstract][Full Text] [Related]
14. Low-dose prednisolone in rheumatoid arthritis: adverse effects of various disease modifying antirheumatic drugs.
Malysheva OA; Wahle M; Wagner U; Pierer M; Arnold S; Häntzschel H; Baerwald CG
J Rheumatol; 2008 Jun; 35(6):979-85. PubMed ID: 18412314
[TBL] [Abstract][Full Text] [Related]
15. Longterm methotrexate use in rheumatoid arthritis: 12 year followup of 460 patients treated in community practice.
Wluka A; Buchbinder R; Mylvaganam A; Hall S; Harkness A; Lewis D; Littlejohn GO; Miller MH; Ryan PF
J Rheumatol; 2000 Aug; 27(8):1864-71. PubMed ID: 10955325
[TBL] [Abstract][Full Text] [Related]
16. Slow-acting anti-rheumatic drug therapy for rheumatoid arthritis.
Clegg DO; Ward JR
Nurse Pract; 1987 Mar; 12(3):44, 49-52. PubMed ID: 2882451
[TBL] [Abstract][Full Text] [Related]
17. Slow acting anti-rheumatic drugs in the treatment of rheumatoid arthritis.
Kovarsky J
Tex Med; 1985 Sep; 81(9):35-9. PubMed ID: 3931276
[No Abstract] [Full Text] [Related]
18. Prescribing trends in disease modifying antirheumatic drugs for rheumatoid arthritis: a survey of practicing Canadian rheumatologists.
Pope JE; Hong P; Koehler BE
J Rheumatol; 2002 Feb; 29(2):255-60. PubMed ID: 11838842
[TBL] [Abstract][Full Text] [Related]
19. Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone.
Pincus T; Marcum SB; Callahan LF
J Rheumatol; 1992 Dec; 19(12):1885-94. PubMed ID: 1294735
[TBL] [Abstract][Full Text] [Related]
20. Current concepts in clinical therapeutics: disease-modifying drugs for rheumatoid arthritis.
Pugh MC; Pugh CB
Clin Pharm; 1987 Jun; 6(6):475-91. PubMed ID: 3319362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
